16 September 1998 (16.09.98)

NTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: WO 00/15266 (11) International Publication Number: **A2** A61K 49/00 (43) International Publication Date: 23 March 2000 (23.03.00) PCT/EP99/06830 (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, (21) International Application Number: BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, (22) International Filing Date: 15 September 1999 (15.09.99) KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, (30) Priority Data:

EP

(71) Applicant (for all designated States except US): GOLDHAM BIOGLAN PHARMA GMBH [DE/DE]; Am Wasserberg 11, D-86441 Zusmarshausen (DE).

(72) Inventors; and

98117598.7

- (75) Inventors/Applicants (for US only): FRANK, Artur [DE/DE]; Am Wasserberg 11, D-86441 Zusmarshausen (DE). GI-ANETTINO, Andreina [IT/IT]; Via Francesco Sapori, 49, I-00143 Roma (IT).
- (74) Agent: WIBBELMANN, Jobst; Wuesthoff & Wuesthoff, Schweigerstrasse 2, D-81541 München (DE).

BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: RADIO-CONTRAST AGENTS

(57) Abstract

An imaging or contrast agent comprising a stereoisomer of a compound with at least one chiral centre, wherein said stereoisomer is in stereoisomeric excess and causes fewer adverse side effects on administration, or is less chemotoxic, than at least one other stereoisomer of said chiral compound.